We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$863M
AUM Growth
-$23.7M
Cap. Flow
-$77.7M
Cap. Flow %
-9.01%
Top 10 Hldgs %
80.4%
Holding
40
New
2
Increased
10
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
ELEV
Elevation Oncology
ELEV
+$1.71M
2
GBIO
Generation Bio
GBIO
+$489K
3
STAA icon
STAAR Surgical
STAA
+$88.9K
4
ANAB icon
AnaptysBio
ANAB
+$87K
5
BLUE
bluebird bio
BLUE
+$73.3K

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$88.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27.3M
3
FOLD
Amicus Therapeutics
FOLD
+$3.23M
4
ALGN icon
Align Technology
ALGN
+$3.16M
5
EHTH icon
eHealth
EHTH
+$1.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
2 Financials 1.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$29.4B
$143M 16.61%
2,138,963
-2,284,406
-52% -$88.6M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$13.3B
$93M 10.78%
1,130,167
-4,402
-0.4% -$366K
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$89.6M 10.38%
9,029,843
-314,259
-3% -$3.23M
UTHR icon
4
United Therapeutics
UTHR
$22.7B
$85M 9.85%
266,914
-845
-0.3% -$224K
BIIB icon
5
Biogen
BIIB
$30.6B
$67M 7.76%
289,050
-908
-0.3% -$197K
STAA icon
6
STAAR Surgical
STAA
$1.25B
$65.8M 7.62%
1,381,619
+2,029
+0.1% +$88.9K
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.06B
$39.3M 4.55%
2,418,841
+3,898
+0.2% +$62.9K
PRTA icon
8
Prothena Corp
PRTA
$468M
$34.4M 3.99%
1,666,378
+2,930
+0.2% +$63.4K
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.81B
$31.9M 3.69%
201,683
+418
+0.2% +$53.7K
ANAB icon
10
AnaptysBio
ANAB
$1.64B
$20.1M 2.33%
803,641
+3,735
+0.5% +$87K
IOVA icon
11
Iovance Biotherapeutics
IOVA
$2.9B
$17M 1.97%
2,116,403
+3,592
+0.2% +$38.5K
RVNC
12
DELISTED
Revance Therapeutics, Inc.
RVNC
$13.5M 1.57%
5,257,086
+9,082
+0.2% +$31K
ALKS icon
13
Alkermes
ALKS
$8.29B
$11.9M 1.38%
495,592
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$11M 1.27%
1,010,833
+5,057
+0.5% +$64.8K
EHTH icon
15
eHealth
EHTH
$40.4M
$10.6M 1.23%
2,350,190
-365,491
-13% -$1.84M
NVCR icon
16
NovoCure
NVCR
$2.02B
$9.63M 1.12%
561,908
– –
ALGN icon
17
Align Technology
ALGN
$12.5B
$9.12M 1.06%
37,772
-11,333
-23% -$3.16M
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.82B
$8.32M 0.96%
405,193
– –
SLRN
19
DELISTED
ACELYRIN
SLRN
$7.56M 0.88%
1,715,180
– –
NVRO
20
DELISTED
NEVRO CORP.
NVRO
$6.32M 0.73%
750,371
– –
CYTK icon
21
Cytokinetics
CYTK
$10.8B
$6.05M 0.7%
111,717
– –
GOSS icon
22
Gossamer Bio
GOSS
$86.1M
$5.66M 0.66%
6,277,093
-114,682
-2% -$85.8K
ELEV
23
DELISTED
Elevation Oncology
ELEV
$4.86M 0.56%
1,800,106
+453,440
+34% +$1.71M
BLUE
24
DELISTED
bluebird bio
BLUE
$4.56M 0.53%
231,668
+3,659
+2% +$73.3K
KPTI icon
25
Karyopharm Therapeutics
KPTI
$44.4M
$4.43M 0.51%
340,146
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q2 2024 Portfolio in Review

As of Q2 2024, Palo Alto Investors held 40 positions worth $863M, down 2.7% from $887M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Palo Alto Investors withdrew a net $77.7M in Q2 2024, closing 1 position and reducing 8 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $27.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Generation Bio worth $424K.

  • Palo Alto Investors's largest Q2 2024 buy was Generation Bio: 15,048 shares worth $424K.
  • Palo Alto Investors added most to Elevation Oncology in Q2 2024, an estimated $1.71M increase.
  • Palo Alto Investors's biggest Q2 2024 reduction was Insmed, cutting an estimated $88.6M.
  • Palo Alto Investors fully exited Alnylam Pharmaceuticals in Q2 2024, selling an estimated $27.3M.
  • Palo Alto Investors's ten largest holdings make up 80% of its $863M portfolio in Q2 2024.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q2 2024.
  • Palo Alto Investors's portfolio value fell 2.7% quarter-over-quarter to $863M.

Based on Palo Alto Investors's 13F filing for Q2 2024, filed 14 Aug 2024.